Do analysts rate NKTX or TCRT?

Nkarta presently has a consensus price target of $10.75, indicating a potential upside of 192.92%. Given Nkarta's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nkarta is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nkarta 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83 Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, NKTX or TCRT?

Nkarta is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nkarta N/A N/A -$104.08M -$1.34 N/A Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A

Is NKTX or TCRT more profitable?

Nkarta's return on equity of -30.90% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Nkarta N/A -30.90% -24.20% Alaunos Therapeutics N/A -165.94% -123.50%

Do analysts prefer TCRT or KPTI?

Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 60.89%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86

Do analysts recommend TCRT or SLGL?

Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 164.18%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Sol-Gel Technologies 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67

Does the media refer more to TCRT or SLGL?

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 1 mentions for Alaunos Therapeutics. Sol-Gel Technologies' average media sentiment score of 1.21 beat Alaunos Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alaunos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sol-Gel Technologies 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TCRT or NERV?

Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 127.27%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Minerva Neurosciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, TCRT or NERV?

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A

Is TCRT or NERV more profitable?

Minerva Neurosciences' return on equity of 0.00% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Minerva Neurosciences N/A N/A -32.63%

Does the media favor TCRT or NERV?

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Minerva Neurosciences' average media sentiment score of 0.75 beat Alaunos Therapeutics' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alaunos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Minerva Neurosciences 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TCRT or ADAG?

Adagene has a consensus target price of $8.00, indicating a potential upside of 108.88%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Alaunos Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alaunos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Adagene 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Which has higher valuation and earnings, TCRT or ADAG?

Alaunos Therapeutics has higher earnings, but lower revenue than Adagene. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alaunos Therapeutics N/A N/A -$4.18M -$2.13 N/A Adagene $7.67M 23.66 -$17.61M N/A N/A

Is TCRT or ADAG more profitable?

Adagene's return on equity of 0.00% beat Alaunos Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alaunos Therapeutics N/A -165.94% -123.50% Adagene N/A N/A N/A

Alaunos Therapeutics (TCRT) Competitors

$2.07 +0.03 (+1.47%)

Closing price 03:59 PM Eastern

Extended Trading

$2.14 +0.07 (+3.38%)

As of 05:28 PM Eastern

Compare

TCRT vs. NKTX, KPTI, SLGL, NERV, and ADAG

Should you buy Alaunos Therapeutics stock or one of its competitors? MarketBeat compares Alaunos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alaunos Therapeutics include Nkarta (NKTX), Karyopharm Therapeutics (KPTI), Sol-Gel Technologies (SLGL), Minerva Neurosciences (NERV), and Adagene (ADAG). These companies are all part of the "pharmaceutical products" industry.

How does Alaunos Therapeutics compare to Nkarta?

Nkarta (NASDAQ:NKTX) and Alaunos Therapeutics (NASDAQ:TCRT) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.

Nkarta is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nkarta	N/A	N/A	-$104.08M	-$1.34	N/A
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A

Nkarta's return on equity of -30.90% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nkarta	N/A	-30.90%	-24.20%
Alaunos Therapeutics	N/A	-165.94%	-123.50%

Nkarta has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, Alaunos Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the broader market.

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Nkarta. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for Nkarta. Nkarta's average media sentiment score of 0.00 equaled Alaunos Therapeutics'average media sentiment score.

Company	Overall Sentiment
Nkarta	Neutral
Alaunos Therapeutics	Neutral

Nkarta presently has a consensus price target of $10.75, indicating a potential upside of 192.92%. Given Nkarta's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nkarta is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nkarta	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

80.5% of Nkarta shares are held by institutional investors. Comparatively, 27.7% of Alaunos Therapeutics shares are held by institutional investors. 9.8% of Nkarta shares are held by insiders. Comparatively, 16.1% of Alaunos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Nkarta beats Alaunos Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Karyopharm Therapeutics?

Alaunos Therapeutics (NASDAQ:TCRT) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, dividends, profitability, risk and valuation.

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Karyopharm Therapeutics'average media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Karyopharm Therapeutics	Neutral

Karyopharm Therapeutics has a consensus price target of $17.17, indicating a potential upside of 60.89%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Alaunos Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Karyopharm Therapeutics	$146.07M	1.66	-$196.04M	-$15.09	N/A

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alaunos Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -129.02%. Karyopharm Therapeutics' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Karyopharm Therapeutics	-129.02%	N/A	-120.29%

Alaunos Therapeutics has a beta of -1.02, meaning that its share price is 202% less volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.8, meaning that its share price is 20% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats Alaunos Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Sol-Gel Technologies?

Alaunos Therapeutics (NASDAQ:TCRT) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sol-Gel Technologies has a consensus target price of $197.50, suggesting a potential upside of 164.18%. Given Sol-Gel Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sol-Gel Technologies is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Alaunos Therapeutics has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

In the previous week, Sol-Gel Technologies had 3 more articles in the media than Alaunos Therapeutics. MarketBeat recorded 4 mentions for Sol-Gel Technologies and 1 mentions for Alaunos Therapeutics. Sol-Gel Technologies' average media sentiment score of 1.21 beat Alaunos Therapeutics' score of 0.00 indicating that Sol-Gel Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sol-Gel Technologies	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alaunos Therapeutics has higher earnings, but lower revenue than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Alaunos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Sol-Gel Technologies	$19.39M	10.83	-$6.13M	-$0.34	N/A

Alaunos Therapeutics has a beta of -1.02, indicating that its share price is 202% less volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.12, indicating that its share price is 12% more volatile than the broader market.

Summary

Sol-Gel Technologies beats Alaunos Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Minerva Neurosciences?

Alaunos Therapeutics (NASDAQ:TCRT) and Minerva Neurosciences (NASDAQ:NERV) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Alaunos Therapeutics has a beta of -1.02, meaning that its stock price is 202% less volatile than the broader market. Comparatively, Minerva Neurosciences has a beta of -0.16, meaning that its stock price is 116% less volatile than the broader market.

Alaunos Therapeutics is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A

Minerva Neurosciences has a consensus price target of $10.50, suggesting a potential upside of 127.27%. Given Minerva Neurosciences' stronger consensus rating and higher probable upside, analysts plainly believe Minerva Neurosciences is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

27.7% of Alaunos Therapeutics shares are owned by institutional investors. Comparatively, 34.6% of Minerva Neurosciences shares are owned by institutional investors. 16.1% of Alaunos Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Minerva Neurosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Minerva Neurosciences' return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Minerva Neurosciences	N/A	N/A	-32.63%

In the previous week, Alaunos Therapeutics and Alaunos Therapeutics both had 1 articles in the media. Minerva Neurosciences' average media sentiment score of 0.75 beat Alaunos Therapeutics' score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alaunos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Minerva Neurosciences	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Minerva Neurosciences beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks.

How does Alaunos Therapeutics compare to Adagene?

Alaunos Therapeutics (NASDAQ:TCRT) and Adagene (NASDAQ:ADAG) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Alaunos Therapeutics has higher earnings, but lower revenue than Adagene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alaunos Therapeutics	N/A	N/A	-$4.18M	-$2.13	N/A
Adagene	$7.67M	23.66	-$17.61M	N/A	N/A

Adagene's return on equity of 0.00% beat Alaunos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alaunos Therapeutics	N/A	-165.94%	-123.50%
Adagene	N/A	N/A	N/A

In the previous week, Alaunos Therapeutics had 1 more articles in the media than Adagene. MarketBeat recorded 1 mentions for Alaunos Therapeutics and 0 mentions for Adagene. Alaunos Therapeutics' average media sentiment score of 0.00 equaled Adagene'saverage media sentiment score.

Company	Overall Sentiment
Alaunos Therapeutics	Neutral
Adagene	Neutral

Alaunos Therapeutics has a beta of -1.02, indicating that its share price is 202% less volatile than the broader market. Comparatively, Adagene has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market.

Adagene has a consensus target price of $8.00, indicating a potential upside of 108.88%. Given Adagene's stronger consensus rating and higher possible upside, analysts clearly believe Adagene is more favorable than Alaunos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alaunos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 9.5% of Adagene shares are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by insiders. Comparatively, 21.2% of Adagene shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Adagene beats Alaunos Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Alaunos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TCRT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TCRT vs. The Competition

Export

Metric	Alaunos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$49.82M	$3.15B	$6.99B	$12.46B
Dividend Yield	N/A	2.05%	2.67%	7.39%
P/E Ratio	-0.97	20.08	27.17	24.24
Price / Sales	N/A	367.14	534.05	96.53
Price / Cash	N/A	57.46	49.24	56.96
Price / Book	2.23	4.42	10.83	6.38
Net Income	-$4.18M	$64.65M	$3.56B	$331.19M
7 Day Performance	-4.17%	0.77%	0.81%	-1.84%
1 Month Performance	3.50%	7.22%	5.61%	0.85%
1 Year Performance	-59.17%	28.94%	32.58%	22.18%

Alaunos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TCRT Alaunos Therapeutics	0.5929 of 5 stars	$2.07 +1.5%	N/A	-60.1%	$49.82M	N/A	N/A	40	High Trading Volume
NKTX Nkarta	3.5345 of 5 stars	$2.78 -3.8%	$10.75 +286.7%	+100.0%	$206.77M	N/A	N/A	140	Gap Down
KPTI Karyopharm Therapeutics	1.5464 of 5 stars	$9.46 +3.7%	$17.17 +81.5%	+137.6%	$206.69M	$151.12M	N/A	380	Options Volume
SLGL Sol-Gel Technologies	4.0399 of 5 stars	$72.67 -1.0%	$197.50 +171.8%	+976.0%	$206.25M	$18.47M	N/A	50	Positive News
NERV Minerva Neurosciences	1.9543 of 5 stars	$4.11 -5.1%	$10.50 +155.5%	+190.9%	$201.73M	N/A	N/A	9	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TCRT) was last updated on 7/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. NKTX, KPTI, SLGL, NERV, and ADAG

How does Alaunos Therapeutics compare to Nkarta?

Summary

How does Alaunos Therapeutics compare to Karyopharm Therapeutics?

Summary

How does Alaunos Therapeutics compare to Sol-Gel Technologies?

Summary

How does Alaunos Therapeutics compare to Minerva Neurosciences?

Summary

How does Alaunos Therapeutics compare to Adagene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alaunos Therapeutics (TCRT) Competitors

TCRT vs. NKTX, KPTI, SLGL, NERV, and ADAG

How does Alaunos Therapeutics compare to Nkarta?

Which has higher earnings and valuation, NKTX or TCRT?

Is NKTX or TCRT more profitable?

Which has more volatility & risk, NKTX or TCRT?

Does the media prefer NKTX or TCRT?

Do analysts rate NKTX or TCRT?

Do insiders and institutionals have more ownership in NKTX or TCRT?

Summary

How does Alaunos Therapeutics compare to Karyopharm Therapeutics?

Does the media refer more to TCRT or KPTI?

Do analysts prefer TCRT or KPTI?

Which has preferable earnings and valuation, TCRT or KPTI?

Do institutionals & insiders believe in TCRT or KPTI?

Is TCRT or KPTI more profitable?

Which has more risk & volatility, TCRT or KPTI?

Summary

How does Alaunos Therapeutics compare to Sol-Gel Technologies?

Do insiders & institutionals hold more shares of TCRT or SLGL?

Do analysts recommend TCRT or SLGL?

Is TCRT or SLGL more profitable?

Does the media refer more to TCRT or SLGL?

Which has better earnings & valuation, TCRT or SLGL?

Which has more risk and volatility, TCRT or SLGL?

Summary

How does Alaunos Therapeutics compare to Minerva Neurosciences?

Which has more risk and volatility, TCRT or NERV?

Which has preferable earnings and valuation, TCRT or NERV?

Do analysts prefer TCRT or NERV?

Do institutionals and insiders hold more shares of TCRT or NERV?

Is TCRT or NERV more profitable?

Does the media favor TCRT or NERV?

Summary

How does Alaunos Therapeutics compare to Adagene?

Which has higher valuation and earnings, TCRT or ADAG?

Is TCRT or ADAG more profitable?

Does the media favor TCRT or ADAG?

Which has more risk and volatility, TCRT or ADAG?

Do analysts prefer TCRT or ADAG?

Do institutionals and insiders believe in TCRT or ADAG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRT vs. The Competition

Alaunos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools